title: A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer.
abstract: OBJECTIVE
  To assess progression-free survival (PFS) and overall survival (OS) in patients with advanced epithelial ovarian cancer receiving the combination of cisplatin (75 mg/m(2) i.v.) and cyclophosphamide (700 mg/m(2) i.v.) (CP), or the combination of paclitaxel (175 mg/m2) followed by cisplatin (75 mg/m2) (TP).
  
  
  METHODS
  One hundred and twenty patients were randomized to receive six cycles of one of the treatments every 3 weeks. If measurable, complete response (CR) or partial response (PR) was determined.
  
  
  RESULTS
  There was a significant difference (p<0.05) in the frequency of response (CR +PR) rates between treatment groups, in favor of paclitaxel containing regimen. The median PFS was 9 months for patients in the CP group and 12 months for patients in the TP group (log-rank p=0.215). The median OS were 24 months and 20 months in TP and CP arms, respectively (log-rank p=0.350). Neutropenia and alopecia were more severe with paclitaxel-containing regimen.
  
  
  CONCLUSIONS
  Although OS and PFS were similar in two arms, TP regimen yielded superior response rates relative to CP, with an acceptable toxicity profile. Therefore, the TP regimen remains the preferred initial treatment option.
authors.affiliation: Theagenion Hospital, Thessaloniki, Greece.
authors.forename: D
authors.initials: D
authors.lastname: Mouratidou
authors.forename: C
authors.initials: C
authors.lastname: Gennatas
authors.forename: V
authors.initials: V
authors.lastname: Michalaki
authors.forename: A
authors.initials: A
authors.lastname: Papadimitriou
authors.forename: C H
authors.initials: CH
authors.lastname: Andreadis
authors.forename: C
authors.initials: C
authors.lastname: Sykiotis
authors.forename: N
authors.initials: N
authors.lastname: Tsavaris
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018269:Carcinoma, Endometrioid / Q000188:drug therapy / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D018282:Cystadenocarcinoma, Mucinous / Q000188:drug therapy / Q000473:pathology; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
chemical_list: D003520:Cyclophosphamide; D017239:Paclitaxel; D002945:Cisplatin